Search clinical trials for: BMS-903452

Total 3175 results

Bristol-Myers Squibb

Completed

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

Healthy Participants

United States
Bristol-Myers Squibb

Completed

Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

Healthy Participants

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

NAFLD | Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

Hungary, Czechia
Bristol-Myers Squibb

Completed

Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants

Thrombosis

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants

Heart Decompensation, Acute

United States
Bristol-Myers Squibb

Completed

Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects

Arthritis

United States
Bristol-Myers Squibb

Withdrawn

Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers

Advanced Solid Tumors

Australia, Singapore
Bristol-Myers Squibb

Terminated

A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy

Breast Cancer

United States
Bristol-Myers Squibb

Completed

MAD Refractory: Solid Tumor QD w/o Break

HER2 or EGFR Expressing Advanced Solid Malignancies

Spain, France
Bristol-Myers Squibb

Completed

Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors

Cancer

Japan
Bristol-Myers Squibb

Completed

Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

Thrombosis

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function

Renal Failure

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 Given to Healthy Participants

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis | Liver Fibrosis | Hepatic Cirrhosis

United States
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan

Neoplasms

Japan
Bristol-Myers Squibb

Completed

Multiple Ascending Dose Study of BMS-777607 in Subjects With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors

Australia
Bristol-Myers Squibb

Terminated

Study of BMS-587101 in Patients With Moderate to Severe Psoriasis

Psoriasis, Moderate to Severe

United States
San Antonio Cancer Institute

Completed

BMS-184476 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb

Withdrawn

Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants

Healthy
Bristol-Myers Squibb

Terminated

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease

United States
Bristol-Myers Squibb

Withdrawn

Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis

Atherosclerotic Cardiovascular Disease
Bristol-Myers Squibb

Recruiting

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

United States
The University of Hong Kong
Caritas Medical Centre, Hong Kong

Not yet recruiting

A Brief Body-mind-spirit Intervention to Promote Positive Emotions

Stress | Emotions
Bristol-Myers Squibb

Withdrawn

A Study to Evaluate the Effect of Food on the Drug Levels of BMS-986196 in Healthy Adult Participants

Healthy Adult Volunteers
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Exposure of Single Ascending Doses of BMS-986369 and the Effect of Food on the BMS-986369 in Healthy Participants

Healthy Volunteer

United States
Yale University
National Institute on Aging (NIA)

Completed

Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

Alzheimer Disease

United States
Matthew Dallos
Bristol-Myers Squibb

Terminated

Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19

Solid Tumor | Sars-CoV2 | Hematological Malignancy

United States
Bristol-Myers Squibb

Completed

Phase 1 Study of Mesothelin-ADC

Advanced Cancer

Japan
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants

Cardiac Failure | Myocardial Failure

United States
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function

Renal Failure | Congestive Heart Failure | Kidney Failure | Cardiac Failure | Myocardial Failure

Poland, Czechia
Bristol-Myers Squibb

Completed

Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants

Thrombosis

United Kingdom
Bristol-Myers Squibb

Terminated

Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

Healthy

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment

Thrombosis | Renal Impairment | Factor XI | ESRD (End-Stage Renal Disease)

United States
Bristol-Myers Squibb

Completed

Single-Dose Pharmacokinetics of BMS-790052 in Participants With Hepatic Impairment

Hepatic Insufficiency

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

BMS-599626 in Treating Patients With Metastatic Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Bristol-Myers Squibb

Completed

Relative Bioavailability Study of Four Experimental Formulations for Alzheimer's Disease

Healthy | Alzheimer's Disease

United States
Bristol-Myers Squibb

Terminated

Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Spain, United States, Belgium, France, Italy, Netherlands, United Kingdom
Bristol-Myers Squibb

Terminated

A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies

Tumors

United States, Belgium
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

BMS-214662 in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Unknown

BMS-188797 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Treatment

Unspecified Adult Solid Tumor, Protocol Specific
Bristol-Myers Squibb

Completed

Absolute Bioavailability of BMS-791325

Hepatitis C Virus Infection

United Kingdom
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer

Breast Cancer

China
Bristol-Myers Squibb

Completed

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC)

Advanced Cancer

United States, Israel, Australia, Austria, Canada, Italy
Imperial College Healthcare NHS Trust
Imperial College London; University of Oxford; Oxford University Hospitals NHS...

Withdrawn

SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations (SABRE)

Lymphoma | Leukemia | Immune Thrombocytopenia | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | Myeloma | Thrombotic Thrombocytopenic Purpura (TTP)

United Kingdom
Bristol-Myers Squibb

Completed

Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Cancer

Australia, United States, Canada
Bristol-Myers Squibb

Completed

Single Ascending Dose (BMS-813160) Study

Accelerated Intimal Hyperplasia

United States
CSL Behring

Completed

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Arthritis, Psoriatic

Italy, United States, Canada, Mexico, Poland, Spain, Germany, Czechia, Russian Federation, Australia, South Africa, Argentina, Hungary
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986454 in Healthy Participants

Healthy Participants

United Kingdom
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Psoriasis

United States, Australia, Canada, Japan, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986325 in Healthy Japanese Participants

Healthy Volunteers

United States

3

Subscribe